Clinical trials: Schizophrenia; Psychosis, open to volunteers
Schizophrenia, Psychosis
Biomarkers in Clozapine-responding Schizophrenia
The outline of the current project is to establish a cohort of patients with treatment refractory schizophrenia eligible for clozapine, to identify clinical and biological characteristics of clozapine responding patients.
- Trial name
- BiCS (NCT05316883)
- Testing
- Clozapine
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Jimmi Nielsen
First Episode Psychosis (FEP)
Dopamine and Insulin in Psychosis
Patients with schizophrenia have a high risk of developing metabolic disorders and current evidence points to an overlap in mechanisms underlying psychiatric symptoms and metabolic disturbances.
- Trial name
- DIPS (NCT07252752)
- Testing
- Intranasal Insulin, Low dose insulin infusion, [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
- Where
- Austria
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Psychosis, Prodromal Schizophrenia
Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk
This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability…
- Conditions
- Psychosis, Prodromal Schizophrenia, Prodromal Symptoms
- Trial name
- SCORES (NCT05131035)
- Testing
- SCORES (Specific COgnitive Remediation with Support)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Northwell Health
Schizophrenia and Schizophrenia Spectrum Psychosis
Feeling Safe Study
The goal of this study is to assess the acceptability and satisfaction with the psychological intervention Sentirnos Seguros (Feeling Safe) in people with psychotic disorders and positive delusional symptoms.
- Trial name
- NCT07234708
- Testing
- Sentirnos Seguros
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Schizophrenia, Alzheimer's Disease Psychosis
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable…
- Trial name
- NCT07230652
- Testing
- LY03020
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Cardio Vascular Disease, Metabolic Syndrome (MetS)
Norwegian Mental Illness Heart Health Study
Norwegian patients with severe mental illnesses (SMI), such as schizophrenia spectrum or bipolar disorder, lose on average 10 years of life compared to mentally healthy individuals. Much of this gap is due to heart disease.
- Conditions
- Cardio Vascular Disease, Metabolic Syndrome (MetS), Severe Mental Disorder, Schizophrenia and Schizophrenia Spectrum Psychosis
- Trial name
- NORMI-Heart (NCT07085923)
- Testing
- Lifestyle Intervention
- Where
- Norway
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Madeleine Elisabeth Angelsen
Comparing Clinical Profile and Prognosis of Schizophrenia Versus Methamphetamine Induced Psychosis, SCHIZOPHRENIA
This Hospital-based Observational Study Employed a Study Will be Conducted in Sohag University Hospital Clinics Aiming to Ensure Cases Presented With Psychosis in Two Phases to Differentiate Into Two Groups a Case of Schizophrenia or a Case of Methamphetamine Induced Psychosis.
This hospital-based observational study employed prospective follow up study will be conducted in sohag university hospital clinics aiming to ensure cases presented with psychosis in two phases to differentiate into 2 groups (a…
- Conditions
- Comparing Clinical Profile and Prognosis of Schizophrenia Versus Methamphetamine Induced Psychosis, SCHIZOPHRENIA, Methamphetamine Induced Psychosis
- Trial name
- NCT07184710
- Volunteers
- 200 people
- Sponsor
- Sohag University
Schizophrenia, Psychosis
Outcomes From Remediation and Behavioural Intervention Techniques
It is currently unknown what factors predict response to Cognitive Behavioural Therapy for Psychosis (CBTp) or Cognitive Remediation Therapy (CR) among individuals with schizophrenia-spectrum disorders, thus the current trial…
- Conditions
- Schizophrenia, Psychosis, Psychotic Disorders, Schizophrenia; Psychosis
- Trial name
- ORBIT (NCT05731414)
- Testing
- Cognitive Behavioural Therapy for Psychosis (CBTp), Cognitive Remediation Therapy (CR), Befriending
- Where
- 2 sites in Canada
- Volunteers
- 360 people
- Sponsor
- University of Toronto
Severe Mental Disorder, Schizophrenia
Prediction and Intervention Effect of Rehabilitation Status for Severe Mental Disorder Patients Based on Multimodal Analysis and AI Agents
Mental health issues represent a major public health and social problem that significantly impacts economic and social development.
- Conditions
- Severe Mental Disorder, Schizophrenia, Schizoaffective Disorder, Paranoid Psychosis
- Trial name
- NCT06904079
- Testing
- Gamified Digital Rehabilitation, Routine Care
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia; Psychosis
Efficacy of Maintenance Repetitive Transcranial Magnetic Stimulation (rTMS) in Auditory Verbal Hallucinations
Repetitive transcranial magnetic stimulation (rTMS) can alleviate persistent auditory verbal hallucinations (AVH) in schizophrenic patients, but the classical procedure with low-frequency stimulation for several weeks upon the…
- Trial name
- MAINSTIM (NCT05550155)
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Caen
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Psychosis, Schizophrenia Disorders
DIALOG: Understanding Disorganisation: A Language-focused Global Initiative in Psychosis
Disorganized speech, language and communication, also called 'formal thought disorder,' is a key part of severe mental illnesses like psychosis and mood disorders.
- Conditions
- Psychosis, Schizophrenia Disorders, Bipolar Affective Disorder, Depressive Disorder
- Trial name
- DIALOG (NCT06978465)
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Psychosis, Schizophrenia Disorders
HYEEG Discourse in Psychosis: A Neurobehavioural Study
This multimodal study explores the mechanisms underlying social dysfunction in individuals with schizophrenia. It focuses on the relationship between disorganized communication and social interaction, aiming to identify…
- Trial name
- DISCOURSE-NB (NCT06978803)
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia Disorders, Psychosis
Magnetoencephalography in Psychosis Program
This research involves the examination of speech, thinking patterns and symptoms and recordings from brain's activity in patients with schizophrenia.
- Trial name
- MEGPSY (NCT06978881)
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Mental Illness, Schizophrenia
Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use
Severe mental illness (SMI) refers to the most burdensome psychiatric conditions. The need to pre-empt the onset of SMI is pressing because once SMI develops, quality of life is poor and available treatments have limited…
- Conditions
- Mental Illness, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- IMAGINE (NCT03601026)
- Testing
- Genetic counselling
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Nova Scotia Health Authority
Psychosis; Schizophrenia-Like, Healthy Controls
Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis
This study, "Psychobiological Follow-up Study of Transition from Prodrome to Early Psychosis", will be conducted in collaboration with the Shanghai Mental Health Center (SMHC) and several data processing sites in the United…
- Trial name
- NCT06542640
- Testing
- Mb-rt-fMRI-NFB, rTMS
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Psychosis
Virtual Reality and Artificial Intelligence in Treatment for Patients With Psychosis
Virtual Reality (VR) has gained momentum in the treatment of various mental health conditions. Despite its potential and emphasis on better use of technology in healthcare strategies, VR therapy for severe mental illness remains…
- Trial name
- RecoVRy (NCT06728241)
- Testing
- RecoVRy, VR Games
- Where
- 2 sites in Norway
- Volunteers
- 150 people
- Sponsor
- Oslo University Hospital
Schizophrenia; Psychosis
Uppsala Psychosis Cohort
A multimodal longitudinal study in early stage psychosis patients and individuals at high risk for psychosis. Healthy controls are included for baseline comparisons.
- Trial name
- UPC (NCT05763966)
- Testing
- No intervention
- Where
- Sweden
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Alzheimer's Disease Psychosis, Parkinson Disease Psychosis
Effect of Food and Age on the Pharmacokinetics of LY03017
This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults.
- Conditions
- Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06793995
- Testing
- LY03017
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
The primary objective for this study is to evaluate whether Rituximab as compared to placebo is a clinically effective treatment for a subgroup of patients suffering from psychosis and/or obsessive-compulsive disorder (OCD) or…
- Conditions
- Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia, Delusional Disorder
- Trial name
- Ra-P-OCD (NCT04323566)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Uppsala University Hospital